Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective cohort study to evaluate the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive unresectable advanced or recurrent gastric cancer

Next Previous
Trial Profile

Retrospective cohort study to evaluate the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive unresectable advanced or recurrent gastric cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EN-DEAVOR

Most Recent Events

  • 31 Oct 2022 Status changed from not yet recruiting to recruiting.
  • 25 Oct 2022 Planned initiation date changed from 24 Oct 2022 to 28 Oct 2022.
  • 17 Oct 2022 Planned initiation date changed from 17 Oct 2022 to 24 Oct 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top